Contents

ESOT PROGRAMME

Monday, 1 October 2007

	Parallel Sessions 1–15	
O001–O006	Session 1. Kidney: Primary outcome parameters	2
O007–O012	Session 2. Hepatocellular carcinoma	3
O013–O018	Session 3. Heart: Immunogenicity	5
O019–O024	Session 4. Cell transplantation	6
O025–O030	Session 5. Kidney: Experimental	8
O031–O041	Session 6. Kidney: New diagnostic parameters	10
O042–O052	Session 7. Living donor & split liver transplantation	13
O053–O063	Session 8. Immune regulation & tolerance	16
O064–O074	Session 9. Kidney: Clinical Immunosuppression I	18
O075–O085	Session 10. Ethics / law / composite tissues	22
O086–O096	Session 11. Kidney: Immunosuppressive therapy & genetic markers	25
O097–O107	Session 12. Donor evaluation. Waiting list	28
O108–O118	Session 13. Liver: Clinical immunosuppression	31
LB01–LB11	Session 14. Late Breakers	34
O119–O129	Session 15. Deceased donation & allocation	37

Tuesday, 2 October 2007

	Parallel Sessions 16–30	
O130–O135	Session 16. Kidney: Translational research	40
O136–O141	Session 17. Liver: Clinical complications	41
O142–O147	Session 18. Living donation	43
O148–O153	Session 19. Islets	44
LB12–LB17	Session 20. Late breakers	46
O154–O164	Session 21. Kidney: Donor organ quality	47
O165–O175	Session 22. Outcome for small bowel & uncommon indications for liver transplantation	51
O176–O186	Session 23. Immune activation & crosstalk	54
O187–O197	Session 24. Kidney: Clinical Immunosuppression II	56
O198–O208	Session 25. IRI & preservation: Mechanisms & protection	59
O209–O214	Session 26. Kidney: Suboptimal donor organs	62
O215–O220	Session 27. Liver: Surgical complications	64
O221–O226	Session 28. Heart: Donor & recipient	66
O227–O232	Session 29. Experimental immunosuppression: Cellular	67
O233–O238	Session 30. Histocompatibility	69

Wednesday, 3 October 2007

	Parallel Sessions 31–41	
O239–O247	Session 31. Kidney: Humoral rejection	71
O248–O256	Session 32. Experimental immunosuppression: Molecular	73
O257–O265	Session 33. Lung	75
O266–O273A	Session 34. Pancreas	77
O274–O282	Session 35. Pediatric transplantation	80
O283–O288	Session 36. Presidential session	82
O289–O297	Session 37. Kidney: Short & long-term complications	84
O298–O306	Session 38. Liver: Immunosuppression & rejection	86

O307–O315 Session 39. Humoral & cellular responses 89
O316–O324 Session 40. Donor viability: Storage, perfusion & resuscitation 91
O325–O333 Session 41. Heart: Clinical immunosuppression 93

Poster Presentations

P001–P014 Cell transplantation 97
P015–P018 Composite tissues 99
P019–P060 Donation / allocation 101
P061–P071 Ethics / law / public policy 111
P072–P189 Clinical immunosuppression 113
P190–P217 Experimental immunosuppression 141
P218–P222 Histocompatibility 148
P223–P260 Immunobiology / basic science 149
P261–P296 Heart 158
P298–P312 Islets 166
P313–P660 Kidney 170
P661–P862 Liver & intestine 256
P863–P871 Lung 304
P872–P899 Pancreas 306
P900–P926 Pediatric transplantation 313
P927–P965 Tissue injury / preservation 318
P966–P969 Xenotransplantation 328

ETCO PROGRAMME

Saturday, 29 September 2007

Oral Presentations

EO01–EO04 Difficult donor 332
EO05–EO08 Living donor 333
EO09–EO14 Education communication 334
EO15–EO20 Practical aspects of coordination 336

Sunday, 30 September 2007

Oral Presentations

EO21–EO24 Donor relatives 338
EO25–EO28 Quality assurance 339
EO29–EO32 Donor detection 340
EO33–EO36 Link donor recipient 341

Saturday, 29 September 2007

Poster Presentations

EP01–ELBP01 Organisation (1) 342
EP08–ELBP02 Organisation (2) 343
EP15–ELBP05 Donor 345

Sunday, 30 September 2007

Poster Presentations

EP20–EP26 Education 348
EP27–ELBP06 Recipient (1) 349
EP34–ELBP09 Recipient (2) 351

Author Index 355